363 related articles for article (PubMed ID: 10662999)
1. [Immunopathogenesis of inflammatory bowel diseases].
Neurath MF; Schürmann G
Chirurg; 2000 Jan; 71(1):30-40. PubMed ID: 10662999
[TBL] [Abstract][Full Text] [Related]
2. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
3. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
Dharmani P; Chadee K
Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
[TBL] [Abstract][Full Text] [Related]
4. Selective immunomodulation in patients with inflammatory bowel disease--future therapy or reality?
van Hogezand RA; Verspaget HW
Neth J Med; 1996 Feb; 48(2):64-7. PubMed ID: 8819802
[TBL] [Abstract][Full Text] [Related]
5. An immunomodulation strategy targeted towards immunocompetent cells or cytokines in inflammatory bowel diseases (IBD).
Heresbach D; Sémana G; Gosselin M; Bretagne MG
Eur Cytokine Netw; 1999 Mar; 10(1):7-15. PubMed ID: 10210767
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of inflammatory bowel diseases: current concepts and future perspectives.
Neurath MF
Arch Immunol Ther Exp (Warsz); 2000; 48(2):81-4. PubMed ID: 10807047
[TBL] [Abstract][Full Text] [Related]
7. Recent understanding of IBD pathogenesis: implications for future therapies.
Kucharzik T; Maaser C; Lügering A; Kagnoff M; Mayer L; Targan S; Domschke W
Inflamm Bowel Dis; 2006 Nov; 12(11):1068-83. PubMed ID: 17075348
[TBL] [Abstract][Full Text] [Related]
8. Alterations of the mucosal immune system in inflammatory bowel disease.
MacDermott RP
J Gastroenterol; 1996 Dec; 31(6):907-16. PubMed ID: 9027661
[TBL] [Abstract][Full Text] [Related]
9. IL-23 in inflammatory bowel diseases and colon cancer.
Neurath MF
Cytokine Growth Factor Rev; 2019 Feb; 45():1-8. PubMed ID: 30563755
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody].
Asakura H
Nihon Rinsho; 2002 Mar; 60(3):531-8. PubMed ID: 11904969
[TBL] [Abstract][Full Text] [Related]
11. Role of cytokines in the pathogenesis of inflammatory bowel disease.
Papadakis KA; Targan SR
Annu Rev Med; 2000; 51():289-98. PubMed ID: 10774465
[TBL] [Abstract][Full Text] [Related]
12. Immune system alterations in patients with inflammatory bowel disease during remission.
Sventoraityte J; Zvirbliene A; Kiudelis G; Zalinkevicius R; Zvirbliene A; Praskevicius A; Kupcinskas L; Tamosiūnas V
Medicina (Kaunas); 2008; 44(1):27-33. PubMed ID: 18277086
[TBL] [Abstract][Full Text] [Related]
13. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
[TBL] [Abstract][Full Text] [Related]
14. Experimental immunomodulatory therapy of inflammatory bowel disease.
Schreiber S
Neth J Med; 1998 Dec; 53(6):S24-31. PubMed ID: 9883011
[TBL] [Abstract][Full Text] [Related]
15. New therapies for inflammatory bowel disease: from the bench to the bedside.
Danese S
Gut; 2012 Jun; 61(6):918-32. PubMed ID: 22115827
[TBL] [Abstract][Full Text] [Related]
16. Cytokine and anti-cytokine therapies for inflammatory bowel disease.
Ogata H; Hibi T
Curr Pharm Des; 2003; 9(14):1107-13. PubMed ID: 12769750
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory mediators in chronic inflammatory bowel diseases.
Gross V; Andus T; Leser HG; Roth M; Schölmerich J
Klin Wochenschr; 1991 Dec; 69(21-23):981-7. PubMed ID: 1798295
[TBL] [Abstract][Full Text] [Related]
18. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome.
Raddatz D; Bockemühl M; Ramadori G
Eur J Gastroenterol Hepatol; 2005 May; 17(5):547-57. PubMed ID: 15827446
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive therapies for inflammatory bowel disease.
Zenlea T; Peppercorn MA
World J Gastroenterol; 2014 Mar; 20(12):3146-52. PubMed ID: 24696600
[TBL] [Abstract][Full Text] [Related]
20. Investigating the role of proinflammatory CD16+ monocytes in the pathogenesis of inflammatory bowel disease.
Koch S; Kucharzik T; Heidemann J; Nusrat A; Luegering A
Clin Exp Immunol; 2010 Aug; 161(2):332-41. PubMed ID: 20456413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
